Everest Medicines (HKSE:01952) Price-to-Tangible-Book : 2.68 (As of May. 29, 2024)

View and export this data going back to 2020. Start your Free Trial

What is Everest Medicines Price-to-Tangible-Book?

As of today (2024-05-29), Everest Medicines's share price is HK$22.10. Everest Medicines's Tangible Book per Share of Dec. 2023 for the quarter that ended in Dec. 2023 was HK$8.26. Hence, Everest Medicines's Price to Tangible Book Ratio of today is 2.68.

The historical rank and industry rank for Everest Medicines's Price-to-Tangible-Book or its related term are showing as below:

HKSE:01952' s Price-to-Tangible-Book Range Over the Past 10 Years
Min: 1.47 Med: 2.59 Max: 3.49
Current: 2.68

During the past 6 years, Everest Medicines's highest Price to Tangible Book Ratio was 3.49. The lowest was 1.47. And the median was 2.59.

HKSE:01952's Price-to-Tangible-Book is ranked better than
51.23% of 1218 companies
in the Biotechnology industry
Industry Median: 2.83 vs HKSE:01952: 2.68

A closely related ratio is called PB Ratio. As of today, Everest Medicines's share price is HK$22.10. Everest Medicines's Book Value per Sharefor the quarter that ended in Dec. 2023 was HK$17.02. Hence, Everest Medicines's P/B Ratio of today is 1.30.

Everest Medicines Price-to-Tangible-Book Historical Data

The historical data trend for Everest Medicines's Price-to-Tangible-Book can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Everest Medicines Price-to-Tangible-Book Chart

Everest Medicines Annual Data

Trend

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Price-to-Tangible-Book

Get a 7-Day Free Trial

3.49

2.64

1.47

2.53

Everest Medicines Semi-Annual Data
	Dec18	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23
Price-to-Tangible-Book	Get a 7-Day Free Trial					2.64	3.27	1.47	2.35	2.53

Competitive Comparison of Everest Medicines's Price-to-Tangible-Book

For the Biotechnology subindustry, Everest Medicines's Price-to-Tangible-Book, along with its competitors' market caps and Price-to-Tangible-Book data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Everest Medicines's Price-to-Tangible-Book Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Everest Medicines's Price-to-Tangible-Book distribution charts can be found below:

* The bar in red indicates where Everest Medicines's Price-to-Tangible-Book falls into.

Everest Medicines Price-to-Tangible-Book Calculation

Everest Medicines's price-to-tangible-book ratio for today is calculated as:

Price to Tangible Book	=	Share Price	/	Tangible Book per Share (Q: Dec. 2023 )
	=	22.10	/	8.26
	=	2.68

It can also be calculated from the numbers for the whole company:

Price to Tangible Book	=	Market Cap	/	Tangible Equity
	=	Market Cap	/	(Total Stockholders Equity	-	Preferred Stock	-	Intangible Assets)

A closely related ratio is called PB Ratio. The difference between Price-to-Tangible-Book Ratio and PB Ratio is that book value other than intangibles are used in the calculation.

Be Aware

Some businesses have very light assets, such as software companies or insurance agencies. The Price-to-Book Ratio does not work well for these companies. Some companies even have negative equity, so the Price-to-Book Ratio cannot be applied to them.

Everest Medicines Price-to-Tangible-Book Related Terms

Thank you for viewing the detailed overview of Everest Medicines's Price-to-Tangible-Book provided by GuruFocus.com. Please click on the following links to see related term pages.

Everest Medicines (HKSE:01952) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Everest Medicines Ltd (HKSE:01952) » Definitions » Price-to-Tangible-Book

Comparable Companies

Traded in Other Exchanges

6HN:Germany

Address

1168 West Nanjing Road, 16th Floor, CITIC Pacific Plaza, Jing’an District, Shanghai, CHN, 200041

Website

https://www.everestmedicines.com

Everest Medicines Ltd is a biopharmaceutical company that integrates discovery, licensing, clinical development, commercialization, and manufacturing of potentially novel or differentiated therapies and vaccines to address critical unmet medical needs initially in the Asia Pacific markets and eventually around the world. Its product pipeline includes; Nefecon (TarpeyoTM), EVER001 (previously known as XNW1011), PTX-COVID19-B, Eravacycline (Xerava), EVER206 (also known as SPR206), and others.

Executives

Fu Wei	2307 Founder of a discretionary trust who can infl
Nova Aqua Limited	2201 Interest of corporation controlled by you
C-bridge Joint Value Creation Limited	2201 Interest of corporation controlled by you
Everest Management Holding Co., Ltd.	2101 Beneficial owner
Ra Capital Management, L.p.	2102 Investment manager
Kolchinsky Peter	2305 Beneficiary of a trust
Kolchinsky Anna Inge Leonore Haas	2202 Interest of your spouse
Ra Capital Healthcare Fund, L.p.	2101 Beneficial owner
Ra Capital Healthcare Fund Gp, Llc	2201 Interest of corporation controlled by you
Fu Wei	2307 Founder of a discretionary trust who can infl
Janchor Partners Limited	2102 Investment manager
C-bridge Capital Gp, Ltd.	2501 Other
Vistra Trust (singapore) Pte. Limited	2501 Other
C-bridge Capital Gp Iv, Ltd.	2201 Interest of corporation controlled by you
C-bridge Iv Investment Nine Limited	2101 Beneficial owner

Everest Medicines (HKSE:01952) Headlines

No Headlines